Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40

Amha Gebre Hiwot Jember, Riaz Zuberi, Fu-Tong Liu, Michael Croft

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Asthma is thought to result from an abnormal expansion of CD4 T cells reactive with airborne allergens, and pathology is controlled by several cytokines of the T helper type 2 (Th2) family. The exact molecules which are involved in generating allergen-reactive T cells are not clear. Studies with blocking reagents or knockout animals have shown that the CD28/B7 interaction partially controls development of allergic asthma in mouse models, but may not be the sole molecule involved. In this report, we have investigated the role of the tumor necrosis factor receptor family member OX40 in allergic inflammation using OX40-deficient mice. OX40 has been shown to participate in regulating clonal expansion and memory development of CD4 T cells and may synergize with CD28. Our studies demonstrate that OX40-/- mice, primed with the model allergen ovalbumin and challenged through the airways with aerosolized antigen, are severely impaired in their ability to generate a Th2 response characterized by high levels of interleukin (IL)-5, IL-4, and immunoglobulin E. Moreover, OX40-/- mice exhibit diminished lung inflammation, including an 80-90% reduction in eosinophilia and mucus production, less goblet cell hyperplasia, and significantly attenuated airway hyperreactivity. These studies highlight the potential importance of OX40 in development of allergic asthma and suggest that targeting OX40 may prove useful therapeutically.

Original languageEnglish (US)
Pages (from-to)387-392
Number of pages6
JournalJournal of Experimental Medicine
Volume193
Issue number3
DOIs
StatePublished - Feb 5 2001

Fingerprint

OX40 Receptor
Asthma
Allergens
Inflammation
T-Lymphocytes
Aptitude
Goblet Cells
Tumor Necrosis Factor Receptors
Interleukin-5
Ovalbumin
Eosinophilia
Mucus
Interleukin-4
Immunoglobulin E
Hyperplasia
Pneumonia
Pathology
Cytokines
Antigens

Keywords

  • Allergy
  • Asthma
  • Costimulation
  • Inflammation
  • OX40

ASJC Scopus subject areas

  • Immunology

Cite this

Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. / Jember, Amha Gebre Hiwot; Zuberi, Riaz; Liu, Fu-Tong; Croft, Michael.

In: Journal of Experimental Medicine, Vol. 193, No. 3, 05.02.2001, p. 387-392.

Research output: Contribution to journalArticle

Jember, Amha Gebre Hiwot ; Zuberi, Riaz ; Liu, Fu-Tong ; Croft, Michael. / Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. In: Journal of Experimental Medicine. 2001 ; Vol. 193, No. 3. pp. 387-392.
@article{42e0c19c26a04632abc0c595c0cb234a,
title = "Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40",
abstract = "Asthma is thought to result from an abnormal expansion of CD4 T cells reactive with airborne allergens, and pathology is controlled by several cytokines of the T helper type 2 (Th2) family. The exact molecules which are involved in generating allergen-reactive T cells are not clear. Studies with blocking reagents or knockout animals have shown that the CD28/B7 interaction partially controls development of allergic asthma in mouse models, but may not be the sole molecule involved. In this report, we have investigated the role of the tumor necrosis factor receptor family member OX40 in allergic inflammation using OX40-deficient mice. OX40 has been shown to participate in regulating clonal expansion and memory development of CD4 T cells and may synergize with CD28. Our studies demonstrate that OX40-/- mice, primed with the model allergen ovalbumin and challenged through the airways with aerosolized antigen, are severely impaired in their ability to generate a Th2 response characterized by high levels of interleukin (IL)-5, IL-4, and immunoglobulin E. Moreover, OX40-/- mice exhibit diminished lung inflammation, including an 80-90{\%} reduction in eosinophilia and mucus production, less goblet cell hyperplasia, and significantly attenuated airway hyperreactivity. These studies highlight the potential importance of OX40 in development of allergic asthma and suggest that targeting OX40 may prove useful therapeutically.",
keywords = "Allergy, Asthma, Costimulation, Inflammation, OX40",
author = "Jember, {Amha Gebre Hiwot} and Riaz Zuberi and Fu-Tong Liu and Michael Croft",
year = "2001",
month = "2",
day = "5",
doi = "10.1084/jem.193.3.387",
language = "English (US)",
volume = "193",
pages = "387--392",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "3",

}

TY - JOUR

T1 - Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40

AU - Jember, Amha Gebre Hiwot

AU - Zuberi, Riaz

AU - Liu, Fu-Tong

AU - Croft, Michael

PY - 2001/2/5

Y1 - 2001/2/5

N2 - Asthma is thought to result from an abnormal expansion of CD4 T cells reactive with airborne allergens, and pathology is controlled by several cytokines of the T helper type 2 (Th2) family. The exact molecules which are involved in generating allergen-reactive T cells are not clear. Studies with blocking reagents or knockout animals have shown that the CD28/B7 interaction partially controls development of allergic asthma in mouse models, but may not be the sole molecule involved. In this report, we have investigated the role of the tumor necrosis factor receptor family member OX40 in allergic inflammation using OX40-deficient mice. OX40 has been shown to participate in regulating clonal expansion and memory development of CD4 T cells and may synergize with CD28. Our studies demonstrate that OX40-/- mice, primed with the model allergen ovalbumin and challenged through the airways with aerosolized antigen, are severely impaired in their ability to generate a Th2 response characterized by high levels of interleukin (IL)-5, IL-4, and immunoglobulin E. Moreover, OX40-/- mice exhibit diminished lung inflammation, including an 80-90% reduction in eosinophilia and mucus production, less goblet cell hyperplasia, and significantly attenuated airway hyperreactivity. These studies highlight the potential importance of OX40 in development of allergic asthma and suggest that targeting OX40 may prove useful therapeutically.

AB - Asthma is thought to result from an abnormal expansion of CD4 T cells reactive with airborne allergens, and pathology is controlled by several cytokines of the T helper type 2 (Th2) family. The exact molecules which are involved in generating allergen-reactive T cells are not clear. Studies with blocking reagents or knockout animals have shown that the CD28/B7 interaction partially controls development of allergic asthma in mouse models, but may not be the sole molecule involved. In this report, we have investigated the role of the tumor necrosis factor receptor family member OX40 in allergic inflammation using OX40-deficient mice. OX40 has been shown to participate in regulating clonal expansion and memory development of CD4 T cells and may synergize with CD28. Our studies demonstrate that OX40-/- mice, primed with the model allergen ovalbumin and challenged through the airways with aerosolized antigen, are severely impaired in their ability to generate a Th2 response characterized by high levels of interleukin (IL)-5, IL-4, and immunoglobulin E. Moreover, OX40-/- mice exhibit diminished lung inflammation, including an 80-90% reduction in eosinophilia and mucus production, less goblet cell hyperplasia, and significantly attenuated airway hyperreactivity. These studies highlight the potential importance of OX40 in development of allergic asthma and suggest that targeting OX40 may prove useful therapeutically.

KW - Allergy

KW - Asthma

KW - Costimulation

KW - Inflammation

KW - OX40

UR - http://www.scopus.com/inward/record.url?scp=0035808782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035808782&partnerID=8YFLogxK

U2 - 10.1084/jem.193.3.387

DO - 10.1084/jem.193.3.387

M3 - Article

C2 - 11157058

AN - SCOPUS:0035808782

VL - 193

SP - 387

EP - 392

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 3

ER -